Papazafiri Panagiota, Avlonitis Nicolaos, Angelou Panagiotis, Calogeropoulou Theodora, Koufaki Maria, Scoulica Efi, Fragiadaki Irene
Department of Animal and Human Physiology, School of Biology, University of Athens, Panepistimiopolis, 15784, Athens, Greece.
Cancer Chemother Pharmacol. 2005 Sep;56(3):261-70. doi: 10.1007/s00280-004-0935-6. Epub 2005 Apr 26.
Previous studies have shown that alkylphosphocholines (APCs) exhibit strong antineoplastic activity against various tumour cell lines in vitro and in several animal models. The current study was designed to investigate the influence of cycloalkane rings on the antiproliferative activity of APCs against a panel of eight human and animal cell lines (PC3, MCF7, A431, Hela, PC12, U937, K562, CHO). Specifically, we explored the effect of the presence of 4-alkylidenecyclohexyl and cycloalkylidene groups in alkoxyethyl and alkoxyphosphodiester ether lipids, respectively. In addition, the haemolytic activity of the new ring-substituted ether phospholipids (EP) was evaluated.
Cells were exposed to various concentrations of the compounds for 72 h. The cytotoxicity was determined with the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] dye reduction assay. Similarly, red blood cells were distributed in 96-well microplates and treated with the test compounds at concentrations ranging from 100 to 6.25 microM for 1 h. After centrifugation, the absorbance of the supernatants was measured at 550 nm.
The majority of the compounds tested exhibited significant cytotoxic activity which depended on both the ring size and position with respect to the phosphate moiety, as well as the head group. Among the cycloalkylidene series the 11-adamantylideneundecyl-substituted N-methylmorpholino EP 13 was the most potent and exhibited broad-spectrum anticancer activity comparable to or superior to that of hexadecylphosphocholine (HePC). All the adamantylidene-substituted EPs were nonhaemolytic (concentration that exhibits 50% haemolytic activity, HC(50), >100 microM). Furthermore, the cyclohexylidene-substituted analogues were more potent against the cell lines tested, with the exception of U937 and K562, than the cyclodecapentylidene-substituted compounds. Hydrogenation of the double bond in the cycloalkylidene-substituted EPs (compounds 14 and 15) resulted in improvement of anticancer activity. Among the 2-(4-alkylidenecyclohexyloxy)ethyl EPs, 2-(4-hexadylidenecyclohexyloxy)ethyl phosphocholine (22) possessed the highest broad-spectrum cytotoxic activity than all the other analogues of this series and was nonhaemolytic (HC(50) >100 microM). In general, the 2-(4-alkylidenecyclohexyloxy)ethyl-substituted EPs were more active against the more resistant cell lines U937, K562 and CHO than HePC.
The presence of cycloalkane rings in the lipid portion of APCs reduces haemolytic effects compared to HePC and in several analogues results in improved antineoplastic activity.
先前的研究表明,烷基磷胆碱(APCs)在体外和多种动物模型中对各种肿瘤细胞系均表现出强大的抗肿瘤活性。本研究旨在探讨环烷烃环对APCs针对一组八种人类和动物细胞系(PC3、MCF7、A431、Hela、PC12、U937、K562、CHO)的抗增殖活性的影响。具体而言,我们分别探究了烷氧基乙基和烷氧基磷酸二酯醚脂质中4-亚烷基环己基和亚环烷基的存在所产生的影响。此外,还评估了新型环取代醚磷脂(EP)的溶血活性。
将细胞暴露于不同浓度的化合物中72小时。采用MTT [3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐] 染料还原法测定细胞毒性。同样,将红细胞分布于96孔微孔板中,并用浓度范围为100至6.25 microM的受试化合物处理1小时。离心后,在550 nm处测量上清液的吸光度。
所测试的大多数化合物均表现出显著的细胞毒性活性,其活性取决于环大小、相对于磷酸基团的位置以及头部基团。在亚环烷基系列中,11-金刚烷基亚甲基十一烷基取代的N-甲基吗啉代EP 13最为有效,表现出与十六烷基磷胆碱(HePC)相当或优于它的广谱抗癌活性。所有金刚烷基亚甲基取代的EPs均无溶血作用(表现出50%溶血活性的浓度,HC(50),>100 microM)。此外,除U937和K562外,亚环己基取代的类似物对所测试的细胞系比亚环癸五烯基取代的化合物更有效。亚环烷基取代的EPs(化合物14和15)中双键的氢化导致抗癌活性提高。在2-(4-亚烷基环己氧基)乙基EPs中,2-(4-己基亚甲基环己氧基)乙基磷胆碱(22)比该系列的所有其他类似物具有最高的广谱细胞毒性活性,且无溶血作用(HC(50) >100 microM)。一般而言,2-(4-亚烷基环己氧基)乙基取代的EPs对更具抗性的细胞系U937、K562和CHO比HePC更具活性。
与HePC相比,APCs脂质部分中环烷烃环的存在降低了溶血作用,并且在几种类似物中导致抗肿瘤活性提高。